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ANN = axillary node negative; DRFS = distant relapse-free survival; ER = estrogen receptor; PCR = polymerase chain reaction; RT = reverse
transcription.
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During the San Antonio Breast Cancer Symposium in
December 2003 two studies were presented that were
designed to validate a recurrence score, derived from a
multigene RT-PCR assay, in patients with axillary node-
negative (ANN) breast cancer [1,2]. Contradictory results
were reported from these studies. The multigene RT-PCR
recurrence score accurately predicted the likelihood of
distant metastasis in a cohort of 668 patients with ANN
breast cancer treated with tamoxifen [1], but failed to
predict recurrence risk in 149 patients who had not
received any adjuvant systemic therapy [2].
The need for identifying new prognostic markers in ANN
breast cancer, such as the multigene RT-PCR recurrence
score, is highly relevant. Risk categories for recurrence are
currently defined according to consensus-based
guidelines using histological and clinical characteristics
[3]. Following these guidelines, up to 85% of ANN breast
cancer patients are candidates for adjuvant systemic
treatment. However, as many as 70–80% of these
patients do not develop distant metastases, and therefore
do not need adjuvant treatment [4]. These patients are
unnecessarily exposed to short-term and long-term side
effects. In order to define risk categories more precisely, a
large number of biologic and molecular markers have been
investigated. However, to date, these often promising
markers cannot be incorporated into clinical practice due
to the lack of standard validation, poor reproducibility, or
weak prognostic power [5].
Recent advances in our knowledge of the human genome
have led to the development of powerful high-performance
screening techniques for molecular analysis. A 70-gene
prognosis profile determined by microarray analysis
appeared strongly predictive for outcome in young
patients with breast cancer [6,7], and is presently in the
process of validation in other series of patients in different
laboratories. A major obstacle for the broad application of
microarray analysis will be the requirement of fresh tumor
tissue. This is necessary as RNA degrades into small
fragments in formalin-fixed paraffin-embedded tissue. RT-
PCR is especially suitable for the analysis of small
fragments of RNA and can accurately measure individual
genes of interest in formalin-fixed paraffin-embedded
tissue [8]. A 92-gene RT-PCR assay on archival formalin-
fixed paraffin-embedded breast cancer tissue has been
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Abstract
During the 2003 San Antonio Breast Cancer Symposium two studies were presented that were
designed to validate a recurrence score, derived from a 21-gene RT-PCR assay, in patients with
axillary node-negative breast cancer. This recurrence score was highly predictive for the risk of
recurrence in 668 patients treated in a large multicenter trial with adjuvant tamoxifen. However, no
prognostic value was found in a small group of patients who were retrospectively selected in a single
institution and who did not receive any adjuvant systemic therapy. Further validation is needed to
establish the prognostic and predictive role of this assay in clinical management.
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shown to be sensitive, specific, and highly reproducible
[9]. Measured levels of estrogen receptor (ER) mRNA,
progesterone receptor mRNA and HER2 mRNA were
concordant with the levels of the respective proteins
measured by immunohistochemistry [9].
The recurrence score presented at the San Antonio
Breast Cancer Symposium by Paik and colleagues [1] and
by Esteva and colleagues [2] was derived from a 21-gene
RT-PCR assay containing 16 cancer-related genes and
five reference genes. Three studies, including a total of
447 patients, were used to select the 21 genes from a
panel of 250 candidate genes with known prognostic
value [1,10,11]. The 16 cancer-related genes were
divided into seven clusters. Higher expression of HER2
(HER2, GRB7), of proliferation markers (Ki-67, STK15,
survivin, cyclin B1, MYBL2), of invasion markers
(stromolysin 3, cathepsin L2) and of the macrophage
marker CD68 was associated with shorter relapse-free
survival. Higher expression of estrogen-associated genes
(ER, progesterone receptor, Bcl2, SCUBE2), GSTM1 and
BAG1 were associated with longer relapse-free survival.
An algorithm was developed to quantify the recurrence
score. Most accent was given to the proliferation-related
genes (+1.04), to the HER2 genes (+0.47), and to the
estrogen-associated genes (–0.34). The maximum
achievable recurrence score was 100. A recurrence score
less than 18 was considered low risk of recurrence, a
score greater than or equal to 31 was considered high risk
of recurrence, and the remaining scores were considered
intermediate risk of recurrence.
Paik and colleagues presented a validation study of the
21-gene RT-PCR recurrence score that evaluated 668 of
the 2617 patients enrolled in the tamoxifen arm of the
NSABP B-14 trial. This arm of the trial randomized
postmenopausal patients with ER-positive ANN breast
cancer to placebo or to tamoxifen. The distribution of the
various risk categories was 51% low risk, 22%
intermediate risk, and 27% high risk. The overall 10-year
distant relapse-free survival (DRFS) rate was 85%. For
patients with a low recurrence score, the 10-year DRFS
rate was 93.2%; for patients with an intermediate
recurrence score, the DRFS rate was 85.7%; and for
patients with a high recurrence score, the DRFS rate was
69.5%.
These data confirm that this multigene RT-PCR-derived
recurrence score could predict relapse-free survival fairly
accurately in ANN breast cancer patients treated with
tamoxifen (P < 0.00001). Multivariate analysis showed that
it did so independently of age and tumor size. As this
recurrence score is a continuous variable, a prediction for
recurrence, with a 95% confidence interval, can be made
for each individual patient.
Somewhat to the contrary, Esteva and colleagues were
unable to confirm these results in a group of patients who
did not receive any form of adjuvant therapy. They
intended to validate the recurrence score in a selection of
patients taken from a cohort of 4428 patients with ANN
breast cancer who received primary surgical therapy, and
radiotherapy if indicated, at the Texas MD Anderson
Cancer Center between 1978 and 1995. Identified were
220 patients who received no adjuvant systemic therapy
and whose tumor blocks were available and contained at
least 5% invasive cancer. Tumor blocks from 149 patients
were evaluable. Sixty-nine percent of these patients were
ER-positive. Thirty-two percent of patients fell into the low-
risk group, 14% into the intermediate-risk group, and 54%
into the high-risk group. For patients with a low recurrence
score, the 10-year DRFS rate was 82%; for patients with an
intermediate recurrence score, the DRFS rate was 62%;
and for patients with a high recurrence score, the DRFS
rate was 78%. No significant correlation between the 21-
gene RT-PCR recurrence score and DRFS was found.
Analysis of standard risk factors revealed an unexpected
association between higher nuclear grade and lower risk
of recurrence (P = 0.02). This association could have
negatively influenced the prognostic value of the
recurrence score in this cohort, as proliferation markers
are dominant denominators in the algorithm that
determines the recurrence score. Another potential
explanation for the discrepant findings of this small group
of patients is selection bias. No more than 5% of ANN
breast cancer patients treated at the Texas MD Anderson
Cancer Center during a 17-year period were identified to
be included in this study. Of these patients, only 68%
were evaluable for analysis. On the contrary, 99% of
eligible patients in the study presented by Paik and
colleagues were evaluable for analysis.
It might also be possible that the recurrence score is
useful in predicting response or lack of response to
tamoxifen of ER-positive patients, but is not a good
predictor for recurrence in general. The recurrence score
was developed in three groups of patients who were
almost all treated with tamoxifen and/or chemotherapy.
Some of the markers in the panel may be more predictive
than prognostic. The estrogen-related markers are
considered to be weak prognostic factors after longer
follow-up, but to be strong predictors for the response to
hormonal therapy [5]. HER2 overexpression appears to be
only a weak unfavorable prognostic factor [5], but is highly
predictive for treatment with trastuzumab and shows a
negative association with the benefit of tamoxifen [12,13].
Using the St Gallen criteria, approximately 15% of all ANN
patients are classified as low risk (grade I, <2 cm, and ER-
positive). The recommendations for these patients are to
treat them either with adjuvant endocrine therapy or with187
no adjuvant therapy. For all other ANN patients with ER-
positive tumors, the St Gallen consensus considers both
endocrine therapy alone and the combination of
chemotherapy and endocrine therapy treatment options.
The threshold above which combination chemotherapy
and endocrine therapy is advised is not well defined, but
should include consideration of the degree of hormone-
receptor positivity, the presence of HER2 overexpression,
the tumor grade, and the proliferation rate [3].
In particular, the genes that dominate the algorithm
determined from the 21-gene RT-PCR-derived recurrence
score represent these features. The recurrence score may
thus be a better tool to discriminate between ANN ER-
positive patients who can be treated with endocrine
therapy alone (low risk), and those who may benefit from
the combination of endocrine therapy and chemotherapy
(intermediate risk and high risk). However, the
discriminative effect of the recurrence score appears no
better than some known prognostic factors or
combinations of known prognostic factors, such as
urokinase-type plasminogen activator and plasminogen
activator inhibitor-1 [14]. In addition, it is not clear whether
intermediate-risk and high-risk patients benefit from
chemotherapy on top of endocrine therapy. Paik and
colleagues analyzed tumors from the tamoxifen only arm of
the NSABP-B20 trial for the 21-gene recurrence score
[1]. It would have been helpful if tumors from the
chemotherapy plus tamoxifen arm were studied as well.
In conclusion, gene profiles determined by multigene RT-
PCR analyses potentially provide powerful tools to tailor
adjuvant systemic treatment. The 21-gene RT-PCR assay
presented at the San Antonio Breast Cancer Symposium
2003 was highly predictive for the risk of recurrence in
668 ANN patients who participated in the NSABP-B14
study and who were treated with adjuvant tamoxifen.
However, no prognostic value was found in a small highly
selected group of patients with ANN breast cancer who
did not receive any adjuvant systemic therapy. Further
validation is needed, particularly for the untreated patients,
and quality control has to be assured. More studies are
needed to establish the prognostic and predictive role of
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